NTI164 for Rett syndrome in girls and young women
Part of Brain & nervous system, Genetic & congenital, Mental health clinical trials.
This study tests an investigational drug called NTI164 in girls and young women with Rett syndrome. It looks at how safe the drug is and whether it helps with symptoms. The study lasts for a period of time, and participants will be monitored closely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Girls or young women aged 4 to 25 years
- Weigh at least 12 kilograms (about 26 pounds)
- Have a confirmed diagnosis of classic/typical Rett syndrome caused by a change in the MECP2 gene
- Must have been stable (no loss of skills) for at least 6 months before the study
- Must have stable epilepsy or no seizures for at least 8 weeks before the study
- Must be able to take study medication by mouth or through a feeding tube
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication called NA-921 in females with Rett syndrome to see if it works better than a placebo. It may be an option for those who have a confirmed MECP2 gene mutation and stable seizure patterns.
This study tests whether the drug mirtazapine can reduce breathing issues in females with Rett syndrome. Participants must have a confirmed MECP2 mutation and specific breathing dysfunction like breath holding or hyperventilation.
This trial tests whether vorinostat is safe and helpful for girls and young women with Rett syndrome. Participants must have a confirmed MeCP2 mutation and be in a stable phase of the condition.
This trial tests a new gene therapy called GCB-002 for girls with Rett syndrome. The treatment aims to help with symptoms by targeting the genetic cause.
This Phase 2 trial studies whether an antioxidant “cocktail” helps children and teens with Rett syndrome compared with a placebo (inactive drink). If you join, you’ll get study assessments and blood tests to see if the treatment is safe and helpful.
This study measures brain and nerve activity (brain signals) to find patterns that match Rett syndrome. It may help researchers better track Rett changes over time and develop more precise ways to measure response in future treatments.
Hear when a new RETT Syndrome With Proven MECP2 Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.